Top Stories
L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM
Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM
Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

Natco Pharma achieves flawless USFDA Inspection
Natco Pharma Limited proudly announces the successful completion of the United States Food and Drug Administration's (USFDA) inspection of its Pharmacovigilance Department. The evaluation, conducted from October 30, 2023, to November 1, 2023, yielded zero observations, affirming Natco's stringent adherence to pharmacovigilance standards.
The inspection encompassed a thorough assessment of Natco's pharmacovigilance procedures for products distributed globally, with a specific focus on the US market. The results affirm that Natco Pharma meets the stringent requirements set forth by the USFDA.
Natco's Corporate Office in Hyderabad was the epicenter of this evaluation, reflecting the company's dedication to maintaining the highest standards in pharmaceutical compliance. This accomplishment underscores Natco Pharma's commitment to ensuring the safety and efficacy of its pharmaceutical products for consumers, both domestically and internationally.
Related News

L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr
4 mins read. August 2, 2024 at 12:33 PM
Download app
Access BlinkX
everywhere
across device
